Active — Not RecruitingPhase 1

IL-8 Receptor-modified CD70 CAR T Cell Therapy in CD70+ Adult Glioblastoma

United States39 participantsStarted 2023-07-25

Plain-language summary

This is a phase I study to assess the safety and feasibility of IL-8 receptor modified patient-derived activated CD70 CAR T cell therapy in CD70+ adult glioblastoma

Who can participate

Age range18 Years – 80 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. = Low level
✓. = Moderate level
✓. = High level

What they're measuring

Safety of 8R-70CAR T-cell therapy in adult patients with de novo CD70+ GBM

Timeframe: 28 days post-infusion

Feasibility of 8R-70CAR T-cell therapy in adult patients with de novo CD70+ GBM

Timeframe: 10 weeks

Trial details

NCT IDNCT05353530

SponsorUniversity of Florida

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2027-12

View on ClinicalTrials.gov More Glioblastoma Multiforme trials